Corneal collagen cross-linking: An introduction and literature review
Post on 10-Dec-2016
d SNew York.
KEYWORDSCollagen cross-linking;Keratoconus;Corneal ectasia;Riboflavin;Ultraviolet A
disease or a sequela of refractive surgery. In the United
intended to halt the progression of keratectasia. The proce-
cross-linking as a means to strengthen a material is not a
ymer industry used UV light to harden adhesives.1 Cross-
corneal fibril diameter increases 4.5% throughout a per-sons life because of an age-dependent glycosylation cross-linking.4-6 Within the lens, crystallins increase inmolecular weight, and rigidity secondary to age-relatedcross-linking.6,7
Disclosure: The author has no financial or other vested interests in the
products used in this literature review.
* Corresponding author: Brandon J. Dahl, O.D., Weed Army Community
Hospital, Optometry Services Box 105109, Fort Irwin, CA 92310
Optometry (2012) 83, 33-42E-mail: email@example.com, which is currently performed in other parts the world,uses ultraviolet (UV) light and riboflavin to strengthen thestromal collagen.
linking with glutaraldehyde is used to stabilize prostheticheart valves.1,3
Cross-linking is also a natural phenomenon occurringwithin the cornea and crystalline lens with age. TheStates, there is no current treatment for keratectasia.Corneal collagen cross-linking (CXL) is a new treatment
new concept. Dentists use UV light to induce cross-linking,which strengthens the material used for fillings.1,2 The pol-Progressive keratectasia is a result of progressive corneal The use of UV light long wave (UVA) irradiation and152
doi9-1839/$ - see front matter 2012:10.1016/j.optm.2011.09.011AbstractBACKGROUND: This literature review analyzes the scientific evidence available regarding cornealcollagen cross-linking (CXL) as a treatment option for progressive keratectasia.METHODS: A literature search was performed using dates from 1990 to August 2010 regarding CXLSpecific areas of focus for the literature review include safety and efficacy of the procedure as a stand-alone treatment or when used in conjunction with Intacs corneal implants (Addition Technology) orphotorefractive keratectomy (PRK).RESULTS: A total of 50 clinical trials and studies were identified, 20 of which met the inclusioncriteria. Results of the included literature support the conclusion that CXL is a safe and efficacioustreatment for progressive keratectasia. The results of CXL alone have shown stabilization or improve-ment in the maximum keratometry readings, best-corrected visual acuity, uncorrected visual acuity,and spherical and cylinder refractive measurements. CXL has been shown to enhance the effects ofIntacs and has been proven successful when used in conjunction with PRK.CONCLUSION: CXL is an effective treatment for limiting the progression of keratectasia, thus reducingthe need for penetrating keratoplasty. CXL has a similar side-effect profile and similar risk level asPRK.Optometry 2012;83:33-42Corneal collagen cross-linkinand literature review
Brandon J. Dahl, O.D., Eric Spotts, O.D.,
Keller Army Community Hospital, West Point, New York; anAmerican Optometric Association. All rAn introduction
James Q. Truong, O.D.
tate University of New York, College of Optometry,ights reserved.
CXL is the result of research commencing in the 1990sintended to identify biological glues that could strengthencorneal collagen.8 Researchers at the Technical Universityof Dresden in Germany noted diabetic patients rarely de-velop keratoconus because of a glycosylation-mediatedcross-linking that strengthens the stromal tissue.8-12 Theirresearch goal was to induce a similar cross-linking effectin nondiabetic corneas using sugars activated by ultravioletlight.10,13 The final result was a procedure using riboflavinand 370-nm UVA irradiation to induce cross-linkingbetween collagen fibrils in the stroma.8,10,13
Riboflavin (the photosensitizing agent), when excited toa triplet state by UV exposure, releases free radicals orreactive oxygen species into the surrounding stroma.4 The
34 Optometry, Vol 83, No 1, January 2012Methods
A literature review using various health science databasesfrom 1990 until August 2010 was performed. The searchstrategy included words pertaining to CXL, any indicationfor this procedure, and for frequently published authors.The search terms include the following:
CXL Collagen cross-linking Progressive keratectasia or progressive corneal ectasia Keratectasia or corneal ectasia treatment Keratoconus and keratoconus treatment
Figure 1 A, Collagen fibril size and arrangement before undergoingCXL. B, Collagen fibril size and spacing after undergoing CXL. Note the in-creased size and spacing of the collagen fibrils post-CXL and the cross-links
between the individual fibrils.free radicals cause hydrogen bond or cross-link formationbetween the amino acids on the collagen chains at the intra-and interhelical levels as well as the intermicrofibrillarlevel.1,10 The intra- and interhelical cross-links cause an in-crease in collagen fiber diameter, and the intermicrofibrillarcross-links lead to an increase in spacing between collagenfibrils (see Figure 1).1,4,10 CXL is a possible treatment incases of keratoconus, pellucid marginal degeneration,post-laser in situ keratomileusis (LASIK) ectasia, bullouskeratopathy, infectious keratitis, and corneal melts. Patientspreviously considered poor candidates may be able toundergo laser refractive surgery if done in conjunctionwith CXL. Kanellopoulos, Anastasios John Kymionis, George
The inclusion criteria were original articles that studiedthe effects of CXL, either alone or in conjunction withIntacs corneal implants (Addition Technology, DesPlaines, Illinois) or photorefractive keratectomy (PRK),in vivo on human subjects. Sample populations needed toinclude at least 10 patients of any age range undergoingCXL who had a previous diagnosis of keratoconus, iatro-genic keratectasia, corneal ulcer, corneal melt, or bullouskeratopathy.
CXL is indicated in progressive keratectasia, such askeratoconus and the associated variants. Depending onthe population studied, approximately 1 in 2,000 people inthe United States suffer from keratoconus,14,16 with 20% ofthose patients eventually requiring a penetrating kerato-plasty.1,14 Keratoconic corneas undergo changes in thecollagen structure and organization as well as changes inthe extracellular matrix.17-20 The alterations, along withkeratocyte apoptosis and necrosis, lead to a 50% reductionin the biochemical resistance of the cornea.8 Individualswith early-to-moderate keratoconus showing signs ofprogression are better candidates for CXL than those withend-stage disease.8 In keratoconic individuals, CXL hasalso shown the ability to potentiate the effects of Intacsand is effective when used with PRK.10,21-24
CXL is indicated in patients who wish to undergocorneal laser corrective surgery but are considered poorcandidates because of corneal thickness considerations.10
CXL is also indicated in patients suffering from keratecta-sia after corneal laser corrective surgery.10,25 In cases ofkeratectasia, Koller et al.26 recommend restricting inclusioncriteria to patients with keratometry readings less than58 diopters and patient age younger than 35 years. Othercorneal conditions currently being studied as possible indi-cations for CXL include corneal melting processes, infec-tious keratitis not responding to treatment, and bullouskeratopathy.10,25,27-30
CXL requires a minimum corneal thickness of 400 mm afterremoval of the epithelium. Individuals with corneas thinnerthan 400 mm should not undergo CXL because of possibleendothelial cell damage.10,25,31,32 Patients with prior Riboflavin and UVA irradiation Riboflavin and UVA cross-linking Corneal collagen glycosylation reaction Wollensak, Gregory Seiler, Theo Spoerl, Ebergard
patients are only able to achieve functional vision with rigid
the biggest reason many researchers argue that epithelial
discomfort, are at less risk of serious infections and willhave much improved healing times.23,24,57,58 Thesearguments, however, do not address the issue of riboflavinabsorption and proper UV shielding. An alternative tocomplete debridement is performing an incompletedebridement in a crosshatch pattern, which can speed thereepithelialization process and reduce postoperative pain(see Figure 2).10 Kanellopoulos22 has suggested using afemtosecond laser to create a pocket 100 mm deep intothe cornea. This allows for riboflavin delivery in two0.1-mL doses into this pocket without significant epithelialcompromise. The patient group only consisted of 10patients; however, the procedure showed to be efficacious,and the patients experienced less postoperative pain.59
Regardless ofwhether epithelial debridement is performed,
UVAexposure, riboflavin shouldbeen assessedon slit lampbi-
Dahl et al Literature Review 35debridement is necessary. The epithelium acts as a barrierto the riboflavin and prevents sufficient absorption leadingto insufficient riboflavin shielding and possible endothelialcell damage.25,31,40,41,54-56 Wollensak and Iomdina55
showed that without epithelial debridement, the efficacyof CXL is decreased to one fifth the normal efficacy. Baioc-chi et al.56 demonstrated in their study that the necessarystromal concentration of riboflavin is only achieved afterepithelial debridement.
Proponents of leaving the epithelium intact arguepatients will experience significantly less postoperativegas permeable contact lenses and would not be able to func-tion without their contact lenses for 1 month. Assessment ofendothelial cell count is recommended so post-CXL endo-thelial cell counts comparisons can be made.23,31,33 Abroad-spectrum topical antibiotic should be initiated 4 timesdaily, 1 to 3 days before the procedure.10
Abad and Panesso10 suggest the use of gaba analogs(gabapentin or pregabalin) twice daily by mouth beginning1 to 2 days before treatment to increase pain tolerance andcomfort levels postoperatively. Prophylactic use of oralacyclovir should be considered, as an isolated case ofherpes keratitis has been reported in a post-CXL individualwith no prior history of keratitis.1,35
CXL is an outpatient procedure performed under topicalanesthesia with the patient in the supine position. Afterapplication of the anesthetic, a lid speculum is applied tomaintain a large aperture. Controversy still exists asto whether epithelial debridement is necessary, although,a 7- to 9-mm epithelial debridement is most oftenutilized.4,8,10,13,21,22,25,28,31,33-53 Riboflavin absorption isincisional refractive surgery (radial keratotomy or astig-matic keratotomy) should not be considered for CXL. Al-terations within the corneal stroma post-CXL, particularlythe contraction of the collagen lamellae, can cause the ker-atotomy incisions to rupture.10 Other contraindications in-clude central corneal opacities and severe dry eye, whichcan hinder reepithelialization.10,25 Individuals who arepregnant, nursing, or have systemic collagen vascular dis-ease should avoid undergoing CXL, as these populationshave not been sufficiently investigated.10
A comprehensive eye examination before CXL, whichincludes refraction, keratometry, topography, and regionalpachymetry is required.10,13,23,33 Some researchers recom-mend that patients discontinue contact lens use approxi-mately 1 month before CXL to assure no corneal warpageis present.10,27,31,34 It should be noted, however, that this isnot always possible for these patients. Many keratoconicomicroscopy in the anterior chamber to assure the cornea issufficiently saturated.10,24,25,34,40,41,54 The cornea issubsequently exposed to UVA irradiation for 30 min-utes,4,8,13,21-25,28,31,36-54,61-63 during which time riboflavin isadded every 2 to 5 minutes to ensure sufficient riboflavinshielding.4,10,13,23,24,28,33,38-41,43-54,61-63 Despite differencesin procedural techniques, the UVA dosing remains consistent:wavelength 3706 5 nm and (maximum absorption of ribofla-vin)62 power 3 mW/cm2 (5 J/cm2).4,8,10,13,21-25,28,31,33-52,54,62
Treatment zone diameter varies depending on which UVsource is used, but the average treatment diameter is7-9 mm.4,8,10,23,24,31,33,36,39-41,47,51-54,61-63 This assures thatonly clear cornea is exposed to theUVirradiation, and the lim-bal cells are protected.10,64
Postoperative care for CXL is very similar to that of PRK.Topical antibiotics are applied 4 times daily for1 week,8,13,21,25,28,31,34,39,41,43,62 and a bandage contact
Figure 2 Cross-hatch epithelial debridement. This method has beensuggested to decrease postoperative pain and speed up wound healing.a 0.1% riboflavin solution in 20% dextran is subsequentlyapplied every 2 to 5 minutes for 30 minutes before applyingany UVA irradiation.4,8,10,13,21-25,28,31,36-55,60-63 Dextran isused to limit edema, maintain a controlled environment, andmaximize the cross-linking effect.10 Additionally, before
individual reported using frequently.51 Patients undergoingCXL are also at risk for endothelial and limbal cell damagecaused by exposure to UV radiation or the free radicalsliberated during cross-linking.10,64 As previously discussed,Koller et al.26 suggest keratometry readings greater than 58diopters, older than 35 years, and BCVA 20/25 or better arerisk factors for failure or complications.
The recommendations for exposure to wavelengthsbetween 180 and 400 nm suggest radiant exposure shouldnot exceed 1 J/cm.2,76 UVA irradiation of 370 nm wave-length at a dose of 3 mW/cm2 (5.4J/cm2) is used duringCXL.4,8,10,13,21-25,28,31,33-52,54,62 With a corneal thickness
36 Optometry, Vol 83, No 1, January 2012lens is left in place until reepithelialization is com-plete.8,10,13,21,25,28,31,33,34,38,40-43,54 Some controversy doesexist surrounding the use of bandage soft contact lenses.Practitioners must weigh the benefit of increased patientcomfort and improved wound healing compared with theincreased risk of microbial keratitis and complications ofsteroid use with soft contact lenses.31,35,65,66 The individualshould be followed up with daily until reepithelialization.The follow-up schedule is 1, 3, 6, and 12 months afterreepithelialization is complete.8,27,31,39 Topography, best-corrected visual acuity (BCVA), pachymetry, keratometry,and intraocular pressure measurements should be obtainedat each follow-up.27,31,34,39 If a preoperative endothelialcell count was obtained, postoperative measurementsshould be repeated.23,33
If gaba analogs were initiated preoperatively, agents arecontinued 1 to 2 days postoperatively.10 Optional topicalmedications include steroids to decrease inflamma-tion,4,8,21,23,25,28,41,62 or nonsteroidal anti-inflammatorymedications (NSAIDs) for pain.10,39,41,42,51,61,67 Whensteroids or NSAIDs are incorporated, they should bediscontinued after 2 to 3 days postoperatively to preventimpeding wound healing.10 Proparacaine 0.5% diluted to0.125% in artificial tears may also be used every 5 minutesto break the pain cycle instead of an NSAID, then every 30to 60 minutes thereafter.10,68 (An NSAID and the propara-caine mixture should not be used in conjunction with eachother, as no studies were found showing they are a safecombination.)
While some studies report no adverse events,8,13,33 theside-effect profile of CXL is similar to that of PRK.10
Individuals should expect blurry vision, lacrimation, andforeign body sensation for at least 24 to 48 hours.4 Blurryvision is transient but can last up to 1 month or longer,depending on the amount of corneal edema present.10
Stromal edema is concentrated in the anterior two thirdsof the stroma and presents as a honeycomb or sponge-like pattern8,69; this should resolve by 3 months post-operatively with concurrent improvement in vision.8,10
The proposed mechanism for the corneal edema is relatedto the complete rarefaction of keratocytes in the anteriorstroma.8,61,67,69 Confocal microscopy found that the edemawas only present in areas devoid of keratocytes.67 The ribo-flavin soak will cause the cornea to be stained yellow; thestaining resolves within 3 to 4 days and will not cause a de-crease in vision.18
Cases of more severe complications, including microbialkeratitis,28,32,70-73 acanthamoeba keratitis,29 herpes kerati-tis,1,35 sterile infiltrates,74 corneal haze,8,13 and decreasedvisual acuity75 have all been reported in the literature.Additionally, a report by Gokhale and Vemuganti51
suggests a possible link between diclofenac and topical an-esthetic use with corneal melt post-CXL. The case involvedthe use of prescription 0.5% proparacaine, which theof at least 400 mm, no endothelial damage has beenreported8,25,31,33,41,47,67,77 Table 1 details the UV damagethresholds for ocular tissues and the correlation with actualexposure during CXL.25
Several clinical measurements have been shownto improve after CXL, including uncorrected visualacuity (UCVA), BCVA, maximum keratometry values,and spherical, spherical equivalent, and cylindricalrefractive measurements. Tables 2 through 5 detail themeasured improvements found in various clinicalstudies.27,31,33,38,39,41,47,62,67,78-82 In addition to theimprovements observed above, eyes with keratoconusalso experienced a significant reduction in 4 of the 7keratoconus indices as detailed in Table 6.27
Double segment Intacs combined with transepithelialCXL showed more significant improvements in UCVA,BCVA, keratometry values, and sphere and cylinder refrac-tive measurements than double segment Intacs alone(see Table 7).24 This study used Intacs with a 6.8-mm innerdiameter, an 8.1-mm outer diameter, and a 150 curvature,which were placed inferior and superiorly in the cornea.Chan et al.23 showed that CXL had additive effects withinferior segment Intacs compared with inferior-segmentIntacs alone. Patients who underwent CXL with inferiorIntacs showed a statistically significant decrease in cylinderrefraction, steep keratometry values, and average
Table 1 UV damage thresholds of ocular tissues comparedwith UV exposure during CXL7
Ocular tissue Exposure during CXL Damage threshold
Epithelium* 5.4 J/cm2 0.120.56 J/cm2
Endothelium 0.32 J/cm2 0.65 J/cm2
0.27 J/cm2 70 J/cm2
0.22 J/cm2 70 J/cm2
Retina 0.22 J/cm2 7.7 J/cm2
UV 5 ultraviolet; CXL 5 corneal collagen cross-linking.* Photokeratitis is not a sequelae when epithelial debridement is
Table 2 Change in maximum keratometry values after CXL
Study Measurement unit * Follow-up
Goldich et al.31 D 1.80 1 yrWollensak et al.33 D 2.01 VariableArbelaez et al.38 D 1.40 1 yrArgrawal39 D 2.47 VariableVinciguerra et al.41 D 1.35 2 yrWittig-Silva et al.47 D 1.45 12 moRaiskup-Wolf et al.62 D 1.91 2 yrRaiskup-Wolf et al.62 D 2.56 3 yrCaporrossi et al.67 D 1.90 3 moJankov et al.78 D 2.14 6 moHoyer et al.79 D 4.34 1236 moFournie et al.80 D 1.68 318 mo
Table 4 Change in corrected visual acuity after cross-linking
Study Measurement unit * Follow-up
Goldich et al.31 Snellen lines 21.0 1 yrWollensak et al.33 Snellen lines 21.26 1 yrArbelaez et al.38 Snellen lines 23.0 1 yrVinciguerra et al.41 Snellen lines 23.0 2 yrWittig-Silva et al.47 Snellen lines 21.0 1 yrRaiskup-Wolf et al.62 Snellen lines 21.0 2 yrCaporrossi et al.67 Snellen lines 21.66 3 mo
* (2) Represents improvement on acuity, (1) represents loss ofacuity.
Dahl et al Literature Review 37keratometry values compared with those patients who onlyreceived Intacs implantation. No statistically significant dif-ference in UCVA, BCVA, spherical refraction, and flat kera-tometry values were observed between the 2 groups (seeTable 8).23 The only details given about the Intacs used inthis study are that either .35 mm, .30 mm, or .25 mm Intacssegments were placed inferiorly.23
CXL and PRK used in combination is an effectivetreatment for keratoconus patients.21,22,83 Kymionis et al.83
performed PRK followed by same-day CXL. The eyesstudied (N 5 14) showed improvements in spherical equiv-alent, defocus, UCVAs and BCVAs, and mean steepkeratometry values (see Table 9).83 Kanellopoulos22
Coskunseven et al.81 D 1.57 512 moGrewal et al.82 None Stable 12 mo
CXL 5 corneal collagen cross-linking; D 5 diopters.* Represents the decrease in maximum keratometry reading after
CXL.showed that simultaneous PRK and CXL (both proceduresperformed the same day) is more effective than subsequentPRK performed 6 months after CXL (see Table 10).22
Conductive keratoplasty and CXL was not shown tobe an effective permutation for the treatment of keratoco-nus as demonstrated by Kymionis et al.46 Patients undergo-ing this series of procedures did experience significant
corneal thickness requirement of 400 mm to preserve
Table 3 Change in UCVA after CXL
Study Measurement unit * Follow-up
Goldich et al.31 Snellen lines 12.0 1 yrArbelaez et al.38 Snellen lines 25.0 1 yrVinciguerra et al.41 Snellen lines 23.6 3 moCaporrossi et al.67 Snellen lines 25.0 1 yr
UCVA 5 uncorrected visual acuity; CXL 5 corneal collagen cross-linking.
* (2) Represents improvement on acuity, (1) represents loss ofacuity.
Approximate value, original data reported in logMAR converted
to Snellen and then Snellen line improvement for data consistency.endothelial integrity.1,22,25,33,37,40,61
Corneal transparency is essential for proper function;corneal fibril arrangement and spacing are essential inimprovement on topography; however, the effect regressedafter 3 months.
When evaluating a new surgical procedure, safety isparamount. During CXL the ocular tissues are exposed toUVA irradiation, which, under normal circumstances,results in damage. The key to maintaining safety withCXL lies in the shielding effect of riboflavin. UVAabsorption in combination with riboflavin is approximately10 times less (.35 mW/cm2) than that of UVA alone(3.4 mW/cm2).10,63 Kolhaas et al.52 found that duringCXL, 70% of the UVA irradiation is absorbed in the ante-rior 200 mm and 20% is absorbed in the next 200 mm of thecornea.52 Minimal UV irradiation penetrates to more poste-rior structures of the eye.25,31,52 These data are consistentwith the expected depth of treatment of approximately300 mm8,13,61 and supports the recommended minimal
Approximate value, original data reported in logMAR converted
to Snellen and then Snellen line improvement for data consistency.maintaining transparency. CXL causes an increase in colla-gen fiber diameter and fibril spacing (see Figure 2).4,36,84 Tomaintain clarity, the collagen fiber diameter cannot exceed
Table 5 Change in sphere, spherical equivalent, andcylinder refraction measurement after CXL
Study Measurement unit (D) Follow-up
Arbelaez et al.38 Sphere 1.26 2 yrWollensak et al.33 Spherical equivalent 1.14 VariableWollensak et al.33 Cylinder 1.2 VariableArbelaez et al.38 Cylinder 1.25 1 yrArgrawal39 Cylinder 1.2 VariableRaiskup-Wolf et al.62 Cylinder 1.2 2 yr
CXL 5 corneal collagen cross-linking; D 5 diopters.
one third the wavelength of visible light (150 nm).85 The Histologic analysis has found that CXL causes a
Table 6 Keratoconus indices and changes in each index after undergoing corneal collagen cross-linking27
Name Description Preoperative Postoperative*
Index of surface variance Curvature variation from the mean curvature 98 95
Index of vertical asymmetry Curvature difference between superior and inferior 1.10 1.09Keratoconus index Compares keratoconus sector with normal sector 1.27 1.25
Center keratoconus index Compares central with peripheral curvature 1.08 1.06
Index of height asymmetry Height difference between superior and inferior 31.4 24.7
Index of height decentration Vertical decentration of height data 0.09 0.09Aberration coefficient Zernike coefficient of the anterior corneal surface 2.29 2.3
* Postoperative values measured at 12 months.
Statistically significant change.
38 Optometry, Vol 83, No 1, January 201212.2% increase in collagen fibril diameter within the anteriorstroma reported in CXL does not approach the threshold andthus does not affect corneal transparency.4,85 Despite thetreatment being concentrated in the anterior stroma, the pos-terior collagen fibrils also increase in diameter after CXL.The anterior fibers increase 9.3% more than the posteriorfibers; however, the posterior fibrils still increase by 4.6%after CXL.4 The increased fiber diameter after CXL maybe secondary to an increase in molecular weight of typeI stromal collagen after CXL as demonstrated on electropho-retic analysis.36
The increased fiber diameter after CXL may be respon-sible for the stromal demarcation line that is evident2 weeks after CXL is performed.10,13 The demarcationline can be seen clinically on slit lamp biomicroscopy.The demarcation line appears as a faint change in cornealreflectivity extending approximately 60%, or 300 mm,into the cornea from the anterior surface.4,10,13 The changein reflectivity is not significant enough to result in anyadverse effect on visual performance.13 No consensus hasbeen obtained as to etiology of the demarcation line. Stud-ies have suggested that the line is a clinical manifestation ofthe depth of treatment or a change in the refractive indexwithin the stroma caused by the induced cross-links, or aresult of an increase in collagen fiber diameter and fibrilspacing.4,10,13Table 7 Efficacy comparison of double-segment Intacsalone versus double-segment Intacs with CXL. Valuesrepresent improvement from preoperative measurements
Measurement Intacs only Intacs/CXL
UCVA* 1.9 3.19BCVA* 1.7 3.09Spherical refraction 2.08 D 2.58 DCylindrical refraction 0.47 D 0.62 DMean K value 2.22 D 2.57 DSteepest K value 1.27 D 2.03 D
CXL 5 corneal collagen cross-linking; D 5 diopters. Note.Values represent improvement from preoperative measurements.
* Improvement measured by number of Snellen line.complete rarefaction of stromal keratocytes in the anterior200 to 300 mm of the stroma as shown in Figure 3.1,8,25,61,84
Keratocytes in the untreated cornea are activated after theapoptotic event and begin repopulating the treated stromaaround 3 months postoperatively. The repopulating kerato-cytes produce hyaluronan, which plays a key role in fibrilspacing,86 increases the stromal resistance to UV damage,and contributes to an increase in extracellular matrixdensity.37,87 Keratocyte repopulation is complete atapproximately 6 months postoperatively.5,8,13,25,37,45,87
Application of the apoptosis inhibitor zinc chloride is notbeneficial, and it weakens the cross-linking effects of theprocedure.61 Because keratocytes are responsible forstromal organization and maintenance, the lack of kerato-cytes at 6 months postoperatively may leave the corneamore prone to a melting process. The rarefaction of kerato-cytes and subsequent repopulation have been confirmedwith confocal microscopy.1,8,88-90
CXL might play a role in preventing progressive kera-tectasia. Progressive keratectasia is accompanied by adecrease in corneal tensile strength. In vitro testing hasfound a significant increase in stromal rigidity afterCXL.48,91 Porcine corneal tissue has shown a 70% increasein rigidity, whereas human tissue samples in vitro haveshown to increase in rigidity by 328%48; however, rigidityincreases are only evident in the anterior 200 mm of theTable 8 Efficacy comparison of inferior segment Intacsalone versus inferior segment Intacs with CXL
Measurement Intacs with CXL Intacs only
UCVA (Snellen)* 6.5 9.5BCVA (Snellen)* 1 1Spherical refraction 0.12 D 0.25 DCylinder refraction 2.73 D 1.48 DSteep K 1.94 D 0.89 DFlat K 1.05 D 0.64 DAverage K 1.34 D 0.21 D
CXL 5 corneal collagen cross-linking; D 5 diopters. Note.Values represent improvement from preoperative measurements.
* Improvement measured by number of Snellen line.
Researchers have also investigated the use of hypo-osmolar riboflavin in patients with corneal thickness lessthan 400 mm.10,54,64 Instead of the riboflavin applicationdescribed above, 2 drops of hypotonic 0.1% riboflavinsolution are added every 10 seconds to swell the corneauntil the corneal thickness is greater than 400 mm.10 It is,
Table 9 Comparison of pre- and postoperativemeasurements in patients undergoing PRK followed by same-day CXL
Measurement Preoperative Postoperative D
23.03 D 21.25 D 1.75 D
Defocus 4.67 D 3.04 D 1.63 DUCVA 0.99 logMAR 0.16 logMAR 0.83 logMARBCVA 0.21 logMAR 0.11 logMAR 0.10 logMARMean steep K 48.20 D 45.13 D 3.07 D
PRK 5 photorefractive keratectomy; CXL 5 corneal collagencross-linking; UCVA 5 uncorrected visual acuity; BCVA 5 best-corrected visual acuity; D 5 diopters.
Dahl et al Literature Review 39cornea.52 The increase in corneal rigidity after CXL coulddecrease the risk of progressive keratectasia.
Corneas having undergone CXL showed a greaterresistance to chemical degradation, which is critical inhalting the progression of keratectasia.8,53 The demon-strated increase in anticollagenase activity is particularlyimportant in individuals with keratoconus or corneal ulcer-ative processes. Keratoconic corneas are more susceptibleto collagenase,8,92 and collagenolytic activity is one ofthe main mechanisms causing corneal ulceration.92,93
An in vitro chemical degradation study53 compared thevulnerability of untreated corneas and CXL-treated corneaswith pepsin, collagenase, and trypsin. Corneas treated byCXL degraded by day 13 with pepsin, day 14 with colla-genase, and day 5 with trypsin. Untreated corneas showeda much greater vulnerability, degrading by day 6 withpepsin and collagenase, and day 2 with trypsin. The benefitof the increased resistance to chemical degradation afterCXL is evident in various case reports28,29,93-95 of patientswith infectious keratitis and bullous keratopathy. Thesubjects showed subjective and clinical improvements invisual acuity and pain levels as well as decreases in opaci-fication and cicatricial corneal tissue after treatment withCXL.28,29,93-95 In cases of keratomycosis, CXL mayimprove amphotericin B effectiveness against Candida
96albicans, Fusarium sp, and Aspergillus fumigatus.
Table 10 Comparison of sequential versus simultaneous CXLand PRK. Values represent the reduction in measurementsafter both procedures
Measurement Sequential Simultaneous
UCVA 0.41 logMAR 0.76 logMARBCVA 0.25 logMAR 0.28 logMARSpherical equivalent 2.50 D 3.20 DMean K reading 2.75 D 3.50 D
CXL 5 corneal collagen cross-linking; PRK 5 photorefractivekeratectomy; D 5 diopters. Note. Values represent the reductionin measurements after both procedures.Researchers are investigating other ways to allow forCXL treatment in patients with less than 400 mm cornealthickness. Kymionis et al.40 have suggested performingpachymetry-guided epithelial debridement instead of com-plete debridement. All areas thinner than 400 mm beforeepithelial debridement on regional pachymetry are leftintact. The procedure would allow individuals with cornealthickness bordering 400 mm to undergo CXL. Kymioniset al.40 reported a case of pachymetry-guided epithelialdebridement. After 9 months, no adverse events were ob-served. Increased follow-up periods and an increased studycohort are needed to verify the safety and efficacy ofpachymetry-guided epithelial debridement.40
Figure 3 Representation of keratocyte apoptosis after CXL with even-tual repopulation beginning at 3 months postoperatively and completing
approximately 6 months postoperatively.however, unclear if the cross-linking effect on an over-hydrated cornea will be the same as on a cornea withnormal hydration.54
Areas for future study include the indication and efficacyof retreatment. Collagen turnover in the cornea ranges from2 to 7 years, which may indicate the need for retreatment ifthe renewed collagen does not exhibit the same increasedstrength and resistance to degradation.10,33 Further researchinto the need for an adjusted nomogram when using PRKand CXL together is required to reduce the likelihood ofovercorrections and necessary retreatment.21 Also, theregularization of the corneal surface could take up to1 year27; therefore, the refractive error could be variableduring that period of regularization. To satisfy the patientsvisual demands, trial contact lenses or frequent spectaclelens replacement may be necessary.
40 Optometry, Vol 83, No 1, January 2012References
1. Dhaliwal J, Kaufman S. Corneal collagen cross-linking: a confocal,
electron, and light microscopy study of eye bank corneas. Cornea
2. Ruyter I. Compositesdcharacterization of composite filling materials:
reactor response. Adv Dent Res 1988;2:22.
3. Golomb F, Schoen J, Smith S, et al. The role of glutaraldehyde-induced
cross-links in calcification of bovine pericardium used in cardiac valve
bioprostheses. Am J Pathol 1987;127:122-30.
4. Wollensak G, Wilsch M, Spoerl E, et al. Collagen fiber diameter in the
rabbit cornea after collagen crosslinking by riboflavin/UVA. Cornea
5. Doxer A, Misof K, Grabner B, et al. Collagen fibrils in the human
corneal stroma: structure and aging. Invest Ophthalmol Vis Sci 1998;
6. Bailey AJ. Structure, function and ageing of the collagens of the eye.
7. Goosey JD, Zingler JS, Kinoshita JH. Cross-linking of the lens
crystallins in a photodynamic system: a process mediated by singlet
oxygen. Science 1980;208:1278-80.
8. Mazzotta C, Balestrazzi A, Traversi C, et al. Treatment of progressive
keratoconus by riboflavin-UVA-induced cross-linking of corneal colla-
gen: ultrastructural analysis by Heidelberg Retinal Tomograph II
in vivo confocal microscopy in humans. Cornea 2007;26:390-7.
9. Sady C, Hosrof K, Nagaraj RH. Advanced Maillard reaction and
crosslinking of corneal collagen in diabetes. Biochem Biophys Res
The authors thank the staff at the West Point optometryclinic, especially Eric Spotts, O.D., and James Q. Truong,O.D. The authors also thank Mary Davidian, M.D.Conclusion
CXL has shown to be effective at limiting the progression ofkeratectasia. To date, the longest reported follow-up hasbeen 6 years. The patient population is significantly reducedin the 6-year follow-up group; however, individuals haveshown good stability.62 Practitioners should consider enroll-ing keratoconus patients in ongoing clinical trials, especiallythose who show signs of progression as defined by changesin topography, keratometry readings, and new onset of ante-rior segment findings such hydrops.8,14,15 Caution should betaken with patients whose keratometry readings are above58 diopters, are older than 35 years, or have BCVA betterthen 20/25 because they are at higher risk for failure and de-creased vision after CXL.26
Patients with microbial keratitis not responding totreatment and bullous keratopathy may also benefit fromenrolling in clinical trials. These patients may not have alarge improvement in vision, but CXL can significantlyimprove their comfort level. A list of the ongoing clinicaltrials investigating CXL can be found on the U.S. NationalInstitutes of Health Web site.97 No timetable is available forwhen and if CXL will be approved for use in the UnitedStates.10. Abad J, Panesso J. Corneal collagen cross-linking induced by UVA
and riboflavin (CXL). Techniques Ophthalmol 2008;6:8-12.
11. Seiler T, Huhle S, Spoerl E, et al. Manifest diabetes and keratoconus: a
retrospective case-control study. Graefes Arch Clin Exp Ophthalmol
12. Kuo IC, Broman A, Pirouzmanesh A, et al. Is there an association
between diabetes and keratoconus? Ophthalmology 2006;113:184-90.
13. Seiler T, Hafezi F. Corneal cross-linking-induced stromal demarcation
line. Cornea 2006;25:1057-9.
14. Rabinowitz YS. Keratoconus. Surv Ophthalmol 1998;42:297-319.
15. Maguire LJ, Lowry JC. Identifying progression of subclinical kerato-
conus by serial topography analysis. Am J Ophthalmol 1991;112:41-5.
16. National Eye Institute. Facts about the cornea and corneal disease.
Keratoconus. Available at: http://www.nei.nih.gov/health/cornealdi-
sease/#h. Accessed February 12, 2006.
17. Tuori AJ, Virtanen I, Aine E, et al. The immunohistochemical compo-
sition of corneal basement membrane in keratoconus. Curr Eye Res
18. Cheng EL, Maruyama I, SundarRaj N, et al. Expression of type XII
collagen and hemidesmosome-associated proteins in keratoconus
corneas. Curr Eye Res 2001;22:333-40.
19. Radner W, Zehemayer M, Skorpik Ch, et al. Altered organization of
collagen in apex of keratoconus corneas. Ophthalmic Res 1998;30:
20. Kenney MC, Nesburn AB, Burgeson RE, et al. Abnormalities of the
extracellular matrix in keratoconus corneas. Cornea 1997;16:345-51.
21. Kanellopoulos JA, Binder PS. Collagen cross-linking (CCL) with
sequential topography-guided PRK. Cornea 2007;26:891-5.
22. Kanellopoulos AJ. Comparison of sequential vs same-day simultaneous
collagen cross-linking and topography guided PRK for treatment of
keratoconus. J Refract Surg 2009;25:S812-8.
23. Chan C, Sharma M, Boxer Wachler B. Effect of inferior-segment
Intacs with and without C3-R on keratoconus. J Cataract Refract
24. Ertan A, Karacal H, Kamburoglu G. Refractive and topographic
results of transepithelial cross-linking treatment in eyes with Intacs.
25. Spoerl E, Mrochen M, Sliney D, et al. Safety of UVA-riboflavin
crosslinking of the cornea. Cornea 2007;26:385-9.
26. Koller T, Mrochen M, Seiler T. Complication and failure rates after
corneal crosslinking. J Cataract Refract Surg 2009;35:1358-62.
27. Koller T, Iseli HP, Hafezi F, et al. Scheimpflug imaging of corneas
after collagen cross-linking. Cornea 2009;28:510-5.
28. Kozobolis V, Labiris G, Gkika M, et al. UV-A collagen cross-linking
treatment of bullous keratopathy combined with corneal ulcer. Cornea
29. Moren H, Malmsjo M, Mortensen J, et al. Riboflavin and ultraviolet A
collagen crosslinking of the cornea for the treatment of keratitis.
30. Ghanem RC, Santhiago MR, Berti TB, et al. Collagen crosslinking
with riboflavin and ultraviolet-a in eyes with pseudophakic bullous
keratopathy. J Cataract Refract Surg 2010;36:1444.
31. Goldich Y, Marcovich A, Barkana Y, et al. Safety of corneal collagen
cross-linking with UV-A and riboflavin in progressive keratoconus.
32. Samaras K, Lake D. Corneal collagen cross linking (CXL): 1 review.
Int Opthalmol Clin 2010;50:89-100.
33. Wollensak G, Spoerl E, Seiler T. Riboflavin/ultraviolet-A-induced
crosslinking for the treatment of keratoconus. Am J Ophthalmol
34. Goldich Y, Barkana Y, Morad Y, Hartstein M, Avni I, Zadok D. Can we
measure corneal biochemical changes after collagen cross-linking in
eyes with keratoconus-a pilot study. Cornea 2009;28:498-502.
35. Rama P, Di Matteao F, Matuska S, et al. Acanthamoeba keratitis with
perforation after corneal crosslinking and bandage contact lens use.
J Cataract Refract Surg 2009;35:788-91.
36. Wollensak G, Redl B. Gel electrophoretic analysis of corneal collagen
after photodynamic cross-linking treatment. Cornea 2008;27:353-6.
Dahl et al Literature Review 4137. Wollensak G, Iomdina E, Dittert D, et al. Wound healing in the rabbit
cornea after corneal collagen cross-linking with riboflavin and UVA.
38. Arbelaez MC, Bernardita S, Vidal C, et al. Collagen cross-linking with
riboflavin and ultraviolet-A light in keratoconus: one year results.
Oman J Ophthalmol 2009;2:33-8.
39. Argrawal V. Corneal collagen cross-linking with riboflavin and
ultraviolet-A light for keratoconus: results in Indian eyes. Indian
J Ophthalmol 2009;57:111-4.
40. Kymionis G, Diakonis V, Coskunseven E, et al. Customized
pachymetric guided epithelial debridement for corneal collagen cross
linking. BMC Ophthalmology 2009;9:10.
41. Vinciguerra P, Albe E, Trazza S, et al. Intraoperative and postoperative
effects of corneal collagen cross-linking on progressive keratoconus.
Arch Ophthalmol 2009;127:1258-65.
42. Zamora K, Males J. Polymicrobial keratitis after a collagen crosslink-
ing procedure with postoperative use of a contact lens: a case report.
43. Rabinowitz Y. Collagen cross-linking: what you should know about
this potential new treatment. Ophthalmology Management 2009;13:
44. Kahn Y, Behrens A. Corneal collagen cross-linking for the treatment
of diseases of the eye. Contemporary Ophthalmology 2009;8:1-8.
45. Hung M. Corneal collagen cross-linking: new hope for patients with
corneal ectasia. Contemporary Optometry 2010;8:1-5.
46. Kymionis G, Kontadakis G, Naoumidi T, et al. Conductive kerato-
plasty followed by collagen cross-linking with riboflavin-UVA-A in
patients with keratoconus. Cornea 2010;29:239-43.
47. Wittig-Silva C, Whiting M, Lamoureax E, et al. A randomized
controlled trial of corneal collagen cross-linking in progressive kerato-
conus: preliminary results. J Refract Surg 2008;24:S720-5.
48. Wollensak G, Spoerl E, Seiler T. Stress-strain measurements of
human and porcine corneas after riboflavin-ultraviolet-A-induced
cross-linking. J Cataract Refract Surg 2003;29:1780-5.
49. Kymionis GD, Portaliou DM, Bouzoukis DI, et al. Herpetic keratitis
with iritis after corneal crosslinking with riboflavin and ultraviolet A
for keratoconus. J Cataract Refract Surg 2007;33:1982-4.
50. Hayes S, OBrart DP, Lamdin LS, et al. Effect of complete epithelial
debridement before riboflavin-ultraviolet-A corneal collagen
cross-linking therapy. J Cataract Refract Surg 2008;34:657-61.
51. Gokhale N, Vemuganti G. Diclofenac-induced acute corneal melt after
collagen cross-linking for keratoconus. Cornea 2010;29:117-9.
52. Kolhaas M, Spoerl E, Schilde T, et al. Biomechanical evidence of the
distribution of cross-links in corneas treated with riboflavin and ultra-
violet A light. J cataract Refract Surg 2006;32:279-83.
53. Spoerl S, Wollensak G, Seiler T. Increased resistance of crosslinked
corneal against enzymatic digestion. Curr Eye Res 2004;29:35-40.
54. Hafezi F, Kanellopoulos J,Wiltfang R, et al. Corneal collagen crosslink-
ing with riboflavin and ultraviolet A to treat induced keratectasia after
laser in situ keratomileusis. J Cataract Refract Surg 2007;33:2035-40.
55. Wollensak G, Iomdina E. Biomechanical and histological changes
after corneal crosslinking with and without epithelial debridement.
J Cataract Refract Surg 2009;35:540-6.
56. Baiocchi S, Mazzotta C, Cerretani D, et al. Corneal crosslinking:
riboflavin concentration in corneal stroma exposed with and without
epithelium. J Cataract Refract Surg 2010;36:186-8.
57. Pinelli R. The refractive surgery society results using C3R. Paper pre-
sented at: The Second International Congress on Crosslinking; De-
cember 8-9, 2006: Zurich, Switzerland.
58. Hafezi F, Mrochen M, Iseli HP, et al. Collagen crosslinking with
ultraviolet-A and hypoosmolar riboflavin solution in thin corneas.
J Cataract Refract Surg 2009;35:621-4.
59. Kanellopoulos AJ. Collagen cross-linking in early keratoconus with
riboflavin in a femtosecond laser-created pocket: initial clinical
results. J Refract Surg 2009;25:1034-7.
60. Sharma N, Boxer-Wachler BS. Corneal collagen CXL with riboflavin
for corneal stabilization. Paper presented at: The American Academyof Ophthalmology Annual Meeting; October 15-18, 2005: Chicago,
61. Wollensak G, Spoerl E, Wilsch M, et al. Keratocyte apoptosis after
corneal collagen cross-linking using riboflavin/UVA treatment.
62. Raiskup-Wolf F, Hoyer A, Eberhard S, et al. Collagen cross-linking
with riboflavin and ultraviolet-A light in keratoconus: long term
results. J Cataract Refract Surg 2008;34:796-801.
63. Wollensak G, Spoerl E, Reber F, et al. Corneal endothelial cytotoxicity
of riboflavin/UVA treatment in vitro. Ophthalmic Res 2003;35:324-8.
64. Snibson G. Collagen cross-linking: a new treatment paradigm in
corneal diseaseda review. Clin Ex Opthalmol 2010;38:141-53.
65. Thoft RA, Mobilia EF. Complications with therapeutic extended wear
soft contact lenses. Int Ophthalmol Clin 1987;21:197.
66. Aquavella JV, del Cerro M, Musco PS, et al. The effect of a collagen
bandage lens on corneal wound healing: a preliminary report.
Ophthalmic Surg 1987;18:570.
67. Caporossi A, Balocchi S, Mazzotta C, et al. Parasurgical therapy for
keratoconus by riboflavinultraviolet type A rays induced
cross-linking of corneal collagen: preliminary refractive results in an
Italian study. J Cataract Refract Surg 2006;32:837-45.
68. Verma S, Corbett MC, Marshall J. A prospective, randomized,
double-masked trial to evaluate the role of topical anesthetics in
controlling pain after photorefractive keratectomy. Ophthalmology
69. Wollensak G, Herbst H. Significance of the lacunar hydration pattern
after corneal cross linking. Cornea 2010;29:899-903.
70. Pollhammer M, Cursiefen C. Bacterial keratitis early after corneal
crosslinking with riboflavin and ultraviolet-A. J Cataract Refract
71. Perez-Santonja JJ, Artola A, Javaloy J, et al. Microbial keratitis after
corneal collagen crosslinking. J Cataract Refract Surg 2009;35:
72. Koppen C, Vyryghem JC, Gobin L, et al. Keratitis and corneal
scarring after UVA/riboflavin cross-linking for keratoconus. J Refract
73. Sharma N, Maharan P, Signh G, et al. Pseudomonas keratitis after
collagen crosslinking for keratoconus: case report and review of
literature. J Cataract Refract Surg 2010;36:517-20.
74. Angunawela RI, Arnalich-Montiel F, Allan BD. Peripheral sterile
corneal infiltrates and melting after collagen crosslinking for keratoco-
nus. J Cataract Refract Surg 2009;35:606-7.
75. Koller T, Mrochen M, Seiler T. Complication and failure rates after
corneal crosslinking. J Cataract Refract Surg 2009;35:1358-62.
76. Matthes R. Guidelines on limits of exposure to ultraviolet radiation of
wavelengths between 180 and 480 nm (incoherent optical radiation).
Health Phys 2004;87:171-86.
77. Henriquez MA, Izquierdo L Jr, Bernilla C, et al. Riboflavin/ultra-
violet a corneal collagen cross-linking for the treatment of kerato-
conus: visual outcomes and Scheimpflung analysis. Cornea 2011;
78. Jankov MR 2nd, Hafezi F, Beko M, et al. [Corneal Cross-linking for
the treatment of keratoconus: preliminary results]. Arq Bras Oftalmol
79. Hoyer A, Raiskup-Wolf F, Spoerl E, et al. [Collagen cross-linking with
riboflavin and UVA light in keratoconusdresults from Dresden].
80. Fournie P, Galiacy S, Arne JL, et al. [Corneal collagen cross-linking
with ultraviolet-A light and riboflavin for the treatment of progressive
keratoconus]. J Fr Ophtalmol 2009;32:1-7.
81. Coskunseven E, Jankov MR 2nd, Hafezi F. Contralateral eye study of
corneal collagen cross-linking with riboflavin and UVA irradiation in
patients with keratoconus. J Refract Surg 2009;25:371-6.
82. Grewal DS, Brar GS, Jain R, et al. Corneal collagen crosslinking
using riboflavin and ultraviolet-A light for keratoconus: one-year
analysis using Scheimpflug imaging. J Cataract Refract Surg 2009;
83. Kymionis G, Kontadakis G, Kounis G, et al. Simultaneous
topography-guided PRK followed by corneal collagen cross-linking
for keratoconus. J Refract Surg 2009;25:S807-11.
84. Mencucci R, Marini M, Paladini I, et al. Effects of riboflavin/UVA
cross-linking on keratocytes and collagen fibers in human corneas.
Clin Ex Opthalmol 2010;38:49-56.
85. Goldman JN, Benedek GB, Dohlman CH, et al. Structural alterations
affecting transparency in swollen human corneas. Invest Ophthal Vis
86. Podskochy A, Fagerholm P. Cellular response and reactive hyaluronan
production in UV-exposed rabbit corneas. Cornea 1998;17:640-5.
87. Podskochy A, Fagerholm R. Repeated UVR exposures cause
keratocyte resistance to apoptosis and hyaluronan accumulation in
the rabbit cornea. Acta Ophthalmol Scand 2001;79:603-8.
88. Kymionis GD, Diakionis VF, Kalyvianaki M, et al. One-year
follow-up of corneal confocal microscopy after corneal cross-linking
in patients with post laser in situ keratomileusis ectasia and keratoco-
nus. Am J Ophthalmol 2009;147:774-8.
89. Croxatto JO, Tytiun AE, Argento CJ. Sequential in vivo confocal
microscopy study of corneal wound healing after cross-linking in
patients with keratoconus. J Refract Surg 2009:1-8.
90. Mazzotta C, Traversi C, Baiocchi S, et al. Corneal healing after
riboflavin ultraviolet-A collagen cross-linking determined by confocal
laser scanning microscopy in vivo: early and late modifications. Am
J Ophthalmol 2008;146:527-33.
91. He X, Spoerl E, Tang J, et al. Measurement of corneal changes
after collagen crosslinking using a noninvasive ultrasound system.
J Cataract Refract Surg 2010;36:1207-12.
92. Kao WW, Vergnes JP, Ebert J, et al. Increased collagenase and gelatin-
ase activities in keratoconus. Biochem Biophys Res Commun 1982;
93. Kenyon K. Inflammatory mechanisms in corneal ulceration. Trans Am
Ophthalmol Soc 1985;83:610-63.
94. Krueger RR, Ramos-Esteban JC, Kanellopoulos AJ. Staged intrastro-
mal delivery of riboflavin with UVA cross-linking in advanced bullous
keratopathy: laboratory investigation and first clinical case. J Refract
95. Iseli H, Thiel M, Hafezi F, et al. Ultraviolet A/Riboflavin corneal
cross-linking for infectious keratitis associated with corneal melts.
96. Sauer A, Letscher-Bru V, Speeg-Schatz C, et al. In vitro efficacy
on antifungal treatment using riboflavin/UV-A (365 nm) combination
and amphotericin B. Invest Opthalmol Vis Sci 2010;51:3950-3.
97. Clinicaltrials.gov. A service of the U.S. National Institutes of Health.
Available at: http://www.clinicaltrials.gov/ct2/results?term5corneal1collagen1crosslinking.
42 Optometry, Vol 83, No 1, January 2012
Corneal collagen cross-linking: An introduction and literature reviewMethodsIndicationsContraindicationsPreoperative careProcedural overviewPostoperative careSide effects